A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
The main purpose of this study is to assess safety & tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Orlando, Florida 32827, United States
Grand Rapids, Michigan 49546, United States
New York, New York 10065, United States
Pittsburgh, Pennsylvania 15232, United States
San Antonio, Texas 78229, United States
Beijing, 100021, China
Marseille, 13005, France
Naples, 80138, Italy
Roma, 00168, Italy
Barcelona, 08023, Spain
Madrid, 28040, Spain